zintick
ARTV Artiva Biotherapeutics-30.7%Stock moveEarnings and guidance

Artiva Stock Plunges 31% After Halting AlloNK Development and Cutting 94% of Staff

The biotech is also exploring strategic alternatives, including a possible merger, sale or liquidation, after two patient deaths and weaker durability data.

By Zintick Team · Editor: Kratik Mehta
Published

Male scientists doing analysis for germs and bacteria with microscope in the laboratory. Scientific experiment. Medical, Lab,
Photo: Perfect Angle Images/Shutterstock.com

Key points

  • Artiva fell 30.7% on Oct. 27, 2026, after halting AlloNK development in an 8-K
  • Company is cutting about 94% of its workforce and exploring strategic alternatives
  • Preliminary cash of about $319.1 million as of Sept. 30, 2026
  • Two Grade 5 safety events were disclosed, one assessed as likely fludarabine toxicity

Artiva Biotherapeutics (Nasdaq: ARTV) fell 30.7% on Tuesday, Oct. 27, 2026, closing at $4.27 from a previous close of $6.16, on volume about 19 times normal. The S&P 500 ETF (SPY) rose 0.56% that session. The drop followed an 8-K and the press release filed with it, in which the company said it would halt all further development of its lead candidate, AlloNK (AB-101).

Trial halted after safety events

The company said longer-term follow-up did not show the durability of clinical response it believes is needed to support continued development. The press release also described two Grade 5 events, or deaths. One, a case of leukoencephalopathy, was assessed as likely related to fludarabine toxicity. A second sudden death was assessed as unrelated to the study treatment, and its cause has not been determined. The planned Phase 3 pivotal trial will not start.

Workforce cut and strategic review

The board approved the discontinuation on Oct. 22, 2026, and the company plans to reduce its workforce by about 94%. Artiva has engaged Leerink Partners as financial advisor to evaluate options that may include a merger, business combination, sale or licensing of assets, or dissolution and liquidation. The company said it cannot yet estimate the total costs of the wind-down, which it expects to incur mostly in the fourth quarter of 2026.

Cash position

Artiva reported preliminary cash, cash equivalents and investments of about $319.1 million as of Sept. 30, 2026. That figure is unaudited and subject to change. The company's cash and equivalents stood at $301.5 million as of June 30, 2026. In the year ended Dec. 31, 2025, it posted a net loss of $83.9 million on no revenue.

The company also canceled a planned presentation at ACR Convergence 2026 and an investor webcast set for Nov. 9, 2026.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

ARTV page →

Filings, figures and price history are on the Artiva Biotherapeutics page.